Over the last century, scientists have embraced the idea of mobilising anti-tumour immune responses in patients with cancer. In the last decade we have seen the rebirth of cancer immunotherapy and its validation in a series of high profile clinical trials following the discovery of several immune-regulatory receptors. Recent studies point towards the tumour mutational load and resulting neoantigen burden as being crucial to tumour cell recognition by the immune system, highlighting a potentially targetable Achilles heel in cancer. In this review we explore the key mechanisms that underpin the recognition of cancerous cells by the immune system and discuss how we may advance immunotherapeutic strategies to target the cancer mutanome in order to stimulate tumour-specific immune responses, ultimately, to improve the clinical outcome for patients with cancer.
Introduction
The concept of cancer immunotherapy originates from observations made by William 
Clinical successes of immune checkpoint therapies
A significant amount of basic and translational research has been directed towards gaining a better understanding of how the immune response to cancer is regulated. A key inflection point in the history of cancer immunotherapy was the discovery of an immune receptor expressed at high levels by in vitro activated T cells, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). 2 Whilst its function was elusive at first, a number of experiments demonstrated the role of CTLA-4 as a co-inhibitory receptor, responsible for the downregulation of T cell activity. In the mid 1990s several groups proposed that CTLA-4 would act as an immune checkpoint restricting the activity of tumour reactive T cells. [3] [4] [5] [6] [7] [8] [9] Inhibition of T cell proliferation and IL-2 secretion was mediated following CTLA-4 activation and subsequent data demonstrated the effective rejection of tumours in murine models of cancer using antibodies against CTLA-4.
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Further evaluation of mechanism of action has suggested that the antibodies can act both by directly blocking inhibitory signals of regulatory T cells and by driving Fcγ receptor mediated depletion of tumour infiltrating regulatory T cells expressing higher levels of CTLA-4 than effector T cells. [10] [11] [12] [13] These key studies gave rise to the concept of immune regulation of T cells involved in The discovery of a second T cell co-inhibitory molecule of the B7 family, programmed death receptor 1 (PD-1) 14 and its ligand programmed death receptor ligand 1 (PD-L1) 15 was later followed by data showing that blockade of the PD-1/PD-L1 axis using monoclonal antibodies could affect similar anti-tumour immune responses in mice with established tumours. 16 The secretion of inflammatory cytokines by infiltrating lymphocytes, for example interferon gamma, leads to the up-regulation of PD-L1 on the tumour cell surface and surrounding tissues, resulting in the inhibition of T cell activity as a result of PD-1/PD-L1 interaction resulting in tumour immune evasion, a process referred to as 'adaptive immune resistance'. 17 
Numerous trials of anti-PD-1 and anti-PD-L1 therapies have demonstrated impressive
clinical responses with survival benefit in a variety of solid [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] and haematological cancers 33, 34 , transforming the outlook for a large number of patients. Currently, nivolumab and pembrolizumab, both monoclonal antibodies to PD-1, are licensed by the FDA for use in advanced melanoma, metastatic non-small cell lung cancer, metastatic squamous cell head and neck cancers and Hodgkin lymphoma ( Table 1 ). rise to the concept of tumour-associated antigens, following which the discovery of several other key self-antigens encoded by gp100, MART-1 and tyrosinase occurred. [38] [39] [40] The identification of tumour-associated antigens, particularly the finding that these were often shared between patients, drew much attention in the field of Metastatic NSCLC 27 Hodgkin lymphoma 33 Metastatic RCC 19 Metastatic squamous cell carcinoma of the head and neck 23 Locally advanced or metastatic urothelial carcinoma 28 Pembrolizumab (PD-1) Metastatic melanoma 25 Metastatic NSCLC 29 Metastatic squamous cell carcinoma of the head and neck 30 Hodgkin lymphoma 34
Atezolizumab (PD-L1) Locally advanced or metastatic urothelial carcinoma 31 Metastatic NSCLC 26, 32 Ipilimumab (CTLA-4) Metastatic melanoma 35 Ipilimumab and Nivolumab to a highly immunogenic tumour cell variant that was rejected by syngeneic mice due to the expression of novel mutated antigens, resulting in a cytotoxic anti-tumoural immune response. 41 A subsequent study showed the presence of a CD8 + T lymphocyte response to a peptide arising from a tumour-specific somatic mutation in the coding region of a nucleic acid helicase, p68, in an ultraviolet light-induced murine tumour. 42 In a separate study, CD4 + T lymphocytes were shown to recognise unique tumour neoantigens expressed exclusively within the tumour cells of an ultraviolet-light induced murine model of cancer. 43 These studies were bridged to human data by the demonstration of tumour infiltrating lymphocytes capable of recognising a tumour neoantigen encoded by mutated cyclindependent kinase 4 (CDK4) in a human melanoma specimen 44 , and of others capable of recognising antigen arising from a mutated beta-catenin gene exclusively found within melanoma cells 45 . A separate study showed the presence of cytotoxic lymphocytes specific to a neoantigen arising from mutated CASP-8 in a squamous cell carcinoma of the oral cavity. 46 These findings provided initial support that, in humans, tumour specific T cells, which we refer to as neoantigen reactive T cells (NARTs), have the capacity to recognise neoantigens found exclusively within the tumour. 
The renaissance of tumour neoantigens in cancer immunology
The renaissance of neoantigens has been facilitated by improvements in next generation sequencing techniques and bioinformatics pipelines, including the development of neoantigen peptide prediction algorithms, on a background of disappointing results from immunotherapeutic strategies targeted against TAAs.
In the last fifteen years, a number of studies have pointed towards the importance of neoantigen-directed immune responses. In one study, T cell responses towards neoantigens arising from five tumour-specific mutations were shown to predominate over those against tumour-associated antigens within the same patient. 47 A separate study showed the presence of neoantigen reactive CD4 + cells in the tumours of patients with melanoma. 48 Importantly, neoantigen specific T cells have also been detected in the peripheral blood of patients with melanoma. 49 Taken together, data from these studies support the role of neoantigens in anti-tumour immunity; however further studies directly comparing the relative contributions of neoantigens versus tumour-associated antigens in the anti-tumoural immune response are necessary. anti-PD-1 therapy. 19, 64 Moreover, colorectal cancer is not typically considered to be a cancer with a high mutational load 64 however clinical benefit from anti-PD-1 therapy is reported in a subgroup of these patients. 65 Patients with DNA mismatch repair deficiency (MMR) were shown to have an increased clinical response to anti-PD-1 therapy likely related to an increased mutational and neoantigen load arising from MMR deficiency in these patients.
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Intratumoural heterogeneity and anti-tumour immunity
The concept of genetic intratumoural heterogeneity is well documented in a variety of solid and haematological cancers. 
T cell receptor (TCR) repertoire and clonality in cancer
The repertoire of antigen specific T cells is generated in the thymus during the process of T cell differentiation as a result of somatic recombination of both alpha and beta chains of the T cell receptor, followed by central deletional tolerance of the most highly self-reactive T cells. The somatic rearrangement of either V and J segments or V, D, J segments of alpha and beta chains respectively, gives rise to the highly variable complementarity determining region 3 (CDR3) of the TCR, key in determining the antigen specificity of individual T cell clones.
The level of mutational burden and genomic heterogeneity demonstrated in a variety of solid cancers could be reflected in the clonality and repertoire of tumour-reactive lymphocytes found within the tumour microenvironment, but data is currently limited.
Tumours with a high mutational load and resulting neoantigen burden may give rise to a more diverse intra-tumoural T cell repertoire due to the large number of antigens presented to the immune system. In line with this, an association between T cell diversity and mutational load has previously been reported through the analysis of reconstructed CDR3 regions from RNAseq data of samples within the TCGA database. 
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As we move closer to achieving our goal of delivering personalised medicine for many of our patients, we must be thorough in our approach. It is clear, that such bespoke approaches to target cancers will involve sequencing and identification of tumour- 84 Successful therapeutic strategies of how best to overcome tumour resistance in this context remain to be elucidated. Despite these challenges, however, there is hope for optimism that we may finally have found an exploitable Achilles heel in our battle against cancer.
